

GAZİ UNIVERSITY
INSTITUTE OF HEALTH SCIENCES
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY

**DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITY
STUDIES ON SOME NOVEL ACYL HOMOSERINE
LACTONE ANALOGUES**

Master of Science Thesis
Pharm. Anooshirvan M. Miandji

Advisor
Prof. Dr. Ningur Noyanalpan

ANKARA

December 2009

GAZİ UNIVERSITY
INSTITUTE OF HEALTH SCIENCES
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY

**DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITY
STUDIES ON SOME NOVEL ACYL HOMOSERINE
LACTONE ANALOGUES**

Master of Science Thesis
Pharm. Anooshirvan M. Miandji

Advisor
Prof. Dr. Ningur Noyanalpan

ANKARA

December 2009

REPUBLIC OF TURKEY
GAZİ UNIVERSITY
INSTITUTE OF HEALTH SCIENCES

A Thesis Submitted By Following Jury in Partial Fulfillment of the
Requirements for Degree of Master of Science in Pharmaceutical
Chemistry Department


Thesis Trial Date **14th January 2010**



Prof. Dr. Ningur Noyanalpan

Gazi University, Faculty of Pharmacy


Jury Supervisor



Prof. Dr. M. Fethi Şahin

Gazi University,

Faculty of Pharmacy



Assoc. Prof. Dr. Gülgün Tınaz

Süleyman Demirel University,

Faculty of Biology

ACKNOWLEDGEMENTS

First thanks must go to my parents, Ibrahim and Pari M. Miandji, whose patience, support, and impeccable understanding allowed me to continue my career.

For all their guidance, both with the theory and practical knowledge that lay therein, I wish to express my sincerest appreciation.

My thesis director, **Prof Dr Ningur Noyanalpan**, played a major role in this study, both in his initial directions in Medicinal Chemistry and in subsequent meetings as I tried to figure out how best to approach QSAR researches. **Prof. Dr. M. Fethi Şahin**, for all his support and contributions, during both my undergraduate and graduate studies. Here, I'd like to express my appreciation to **Dr. Yasemin Dünder** for her friendly helps during the synthesis stage. Meanwhile, I like to appreciate **Assoc. Prof . Dr. Gülgün Tınaz** (Department of Biology, Süleyman Demirel University) for her valuable contribution to the vitro test designs, methods and applications. **Prof . Dr. Erdem Büyükbingöl** (Department of Pharmaceutical Chemistry, Ankara University) for his contribution to the molecular modeling designs and applications. Thanks to department of Pharmaceutical Microbiology of Faculty of Pharmacy for their contributions during biological tests and activities. Finally, I would like to express my deep appreciation to all the members of the Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, for all their patience, support and contribution.

CONTENTS

Acceptance and Approval.....	<u>III</u>
Acknowledgement	<u>IV</u>
Contents	<u>V</u>
Figures,	<u>IX</u>
Tables	<u>X</u>
Abbreviation.....	<u>XI</u>
1. INTRODUCTION	<u>1</u>
2. GENERAL INFORMATION	<u>6</u>
2.1 Antibiotics and Bacteria	<u>6</u>
2.2 Quorum Sensing	<u>9</u>
2.2.1 N-Alkanoyl- and N-aroyl-Homoserine Lactone-Dependent QS	<u>11</u>
2.2.2 AHL Biosynthesis	<u>12</u>
2.2.3 Biofilm Formation	<u>14</u>
2.2.4 Biofilms and Infectious Diseases	<u>16</u>
2.2.5 Pseudomonas aeruginosa Biofilms	<u>17</u>
2.2.6 Host Defense and Biofilm	<u>18</u>

2.3 Inhibitors Activity	<u>18</u>
2.4 Microwave Assisted Synthesis	<u>21</u>
2.4.1 Thermal vs. Nonthermal Effects	<u>22</u>
2.5 Design of the Active Species	<u>23</u>
2.5.1 Scope of the Study and Design of the Active Species.....	<u>23</u>
3. MATERIALS AND METHODS	<u>27</u>
3.1 Chemistry	<u>27</u>
3.1.1 General Procedure for the Synthesis of 2(3H)- Benzoxazolone Derivatives	<u>27</u>
3.1.2 General Procedure for the Synthesis of 3-acyl- 2(3H)-Benzoxazolone Derivatives	<u>28</u>
3.2 Antibacterial Activity.....	<u>28</u>
3.2.1 Microdilution Method	<u>28</u>
3.3 Quorum Sensing Inhibitory Activities	<u>30</u>
3.3.1 Test for the Inhibition of Violacein Production in Chromobacterium Violaceum	<u>30</u>
3.3.2 Violacein Extraction	<u>31</u>
4. RESULTS.....	<u>32</u>
4.1 Chemical Results	<u>32</u>

3-Decanoyl-1,3-benzoxazol-2(3 <i>H</i>)-one (AMM33	<u>32</u>
3-Octanoyl-1,3-benzoxazol-2(3 <i>H</i>)-one (AMM34.....	<u>32</u>
3-Heptanoyl-1,3-benzoxazol-2(3 <i>H</i>)-one (AMM40.....	<u>33</u>
5-Chloro-3-decanoyl-1,3-benzoxazol-2(3 <i>H</i>)-one (AMM37)	<u>33</u>
5-Chloro-3-octanoyl-1,3-benzoxazol-2(3 <i>H</i>)-one (AMM38)	<u>34</u>
5-Chloro-3-heptanoyl-1,3-benzoxazol-2(3 <i>H</i>)-one (AMM39)	<u>34</u>
3-Decanoyl-6-methyl-1,3-benzoxazol-2(3 <i>H</i>)-one (AMM43)	<u>35</u>
6-Methyl-3-octanoyl-1,3-benzoxazol-2(3 <i>H</i>)-one (AMM44)	<u>35</u>
3-Heptanoyl-6-methyl-1,3-benzoxazol-2(3 <i>H</i>)-one (AMM45).....	<u>36</u>
3-Heptanoyl-5-methyl-1,3-benzoxazol-2(3 <i>H</i>)-one (AMM46).....	<u>36</u>
 4.2 Biological Activities Results	 <u>37</u>
4.2.1 Antibacterial Activity Results	<u>37</u>
4.2.2 QSI Activity Results.....	<u>38</u>
4.2.2.1 Inhibition of Violacein Production	<u>38</u>
4.3 Molecular Modeling Study Results	<u>39</u>

5. DISCUSSION	<u>40</u>
6. CONCLUSION.....	<u>45</u>
7. SUMMARY	<u>46</u>
8. ÖZET	<u>48</u>
REFERENCES	<u>53</u>
CURRICULUM VITAE.....	<u>58.</u>

FIGURES

Figure 1: The general structure of AHL and designed molecules.

Figure 2: The structural similarity between (A) the main AHL molecule and (B) our candidates.

Figure 3: Appropriate treatment that injures bacteria without harming cells of the host.

Figure 4: Schematic illustration in a simplified bacterial cell and major antibiotic actions.

Figure 5: In vitro applications of antibiotics.

Figure 6: Structures of some bacterial QS signal molecules

Figure 7: Biosynthesis of 3-oxo-C6-HSL and pC-HSL

Figure 8: AHL in binding site target LuxR family protein

Figure 9: The five stages of biofilm development.

Figure 10: The schematic illustration of QS regulation inside the bacterium cell.

Figure 11: Schematic illustration of QSI inside the bacterium cell.

Figure 12: A schematic illustration of electromagnetic radiation in a microwave synthesizer

Figure 13: There are many sites on these molecules that can be modified subsequently turning them into inhibitors.

Figure 14: Molecular modeling of AMM38 and AMM40 competition with the autoinducer in binding site of quorum sensing protein LasR.

Figure 15: *AHL types in P. aeruginosa*

Figure 16: Synthetic route of the title compounds.

TABLES

Table 1: List of derivatives of synthesized candidates and substitutions.

Table 2: Standard antibiotic solutions were dissolved in appropriate solvents recommended by CLSI guidelines.

Table 3: List of antibacterial activities of our candidate in comparison with classic test antibiotics


Table 4: Results of compounds caused inhibition

Table 5: Main chemical structure and list of substitutions

Table 6: QSI results

ABBREVATIONS

AHL	<i>N</i> -acyl-L-homoserine lactone
EF-2	Elongation factor 2
LuxI	LuxI enzyme synthesizes LuxR
LuxR	LuxR receptor is the site of interaction with quorum-sensing signals and inhibitors
QS	Quorum Sensing
QSI	Quorum Sensing Inhibitor
QSP	Quorum Sensing Binding Protein



**The Language of Bacteria
is The language of Life.**

miandji

1. INTRODUCTION

“The majority of the cells in our body are not our own, nor are they even human. They are bacterial. Since the hidden strands of fungi waiting to grow among our toes, to the kilo of bacterial material in our intestines, we are finest observed as walking "super organisms", most complex collections of human cells, bacteria, fungi and viruses.

That's the opinion of researchers at Imperial College London who published a paper in *Nature Biotechnology* Oct. 6 describing how these microbes interact with the body. The scientists concentrated on bacteria. More than 500 different species of bacteria exist in our bodies, making up more than 100 trillion cells. Because our bodies are made of only some several trillion human cells, we are somewhat out numbered by the aliens. It follows that most of the genes in our bodies are from bacteria, too.

Luckily for us, the bacteria are on the whole commensal, sharing our food but doing no real harm. In fact, they are often beneficial: Our commensal bacteria protect us from potentially dangerous infections. They do this through close interaction with our immune systems.

We have known for some time that many diseases are influenced by a variety of factors, including both genetics and environment, but the concept of this superorganism could have a huge impact on our understanding of disease processes. The approach could apply to research on insulin-resistance, heart disease, some cancers and perhaps even some neurological diseases.

Following the sequencing of the human genome, scientists quickly saw that the next step would be to show how human genes interact with environmental factors to influence the risk of developing disease, the aging process and drug action. But because environmental

factors include the gene products of trillions of bacteria in the gut, they get very complex indeed. The information in the human genome itself, 3 billion base pairs long, does not help to reduce the complexity.

The human genome provides only scant information. The discovery of how microbes in the gut can influence the body's responses to disease means that we now need more research into this area. Understanding these interactions will extend human biology and medicine well beyond the human genome and help elucidate novel types of gene-environment interactions, with this knowledge ultimately leading to new approaches to the treatment of disease.

Human "super-organism" concept could have a huge impact on how we develop drugs, as individuals can have very different responses to drug metabolism and toxicity.

The microbes can influence things such as the pH levels in the gut and the immune response, all of which can have influences on the effectiveness of drugs." ^{1,2}

Researches focused on bacterial behaviors and communication tools will lead us to understand how their communities interact. We know that Quorum sensing (QS) is bacterial communication phenomenon. QS in pathogens is the core of these studies. QS signaling systems of pathogens are central regulators for the expression of virulence factors and represent highly attractive targets for the development of novel therapeutics. For example, in *P. aeruginosa*, QS systems are also involved in elevated antibiotic tolerance of biofilms as well as elevated tolerance to the activity of the innate immune system. The topic of biofilm is essential to consider in researches focused over pathogen bacteria.

“Formation of a biofilm begins with the attachment of free-floating microorganisms to a surface. These first colonists adhere to the surface initially through weak, reversible van der Waals forces. If the colonists are not immediately separated from the surface, they can anchor themselves more permanently using cell adhesion structures such as pili.”³

“The first colonists facilitate the arrival of other cells by providing more diverse adhesion sites and beginning to build the matrix that holds the biofilm together. Some species are not able to attach to a surface on their own but are often able to anchor themselves to the matrix or directly to earlier colonists. It is during this colonization that the cells are able to communicate via QS using such products as *N*-acyl homoserine lactones (AHL).

Gram-negative bacteria commonly use AHL as QS signal molecules. The use of signal molecule based drugs to attenuate bacterial pathogenicity rather than bacterial growth is attractive for several reasons, particularly considering the emergence of increasingly antibiotic-resistant bacteria. Compounds capable of this type of interference have been termed anti-pathogenic drugs. A large variety of synthetic AHL analogues and natural product libraries have been screened and a number of QS inhibitors (QSI) have been identified. Promising QSI compounds have been shown to make biofilms more susceptible to antimicrobial treatments, and are capable of reducing mortality and virulence as well as promoting clearance of bacteria in experimental animal models of infection.”⁴

Concern about the synthesis of some novel AHL analogues has been the main subject of discussion for two years in the department of Pharmaceutical Chemistry . We were wondering how we could mimic AHL molecules which would inhibit binding sites without the effects of

antibiotics. The interface between these two activities is not clear yet and still constitutes a topic of discussion. Early this year we tried some novel techniques to synthesize some designed models by using a microwave synthesizer.

The general strategy of our design for the potentiation of Quorum Sensing Inhibitors (QSIs) has been to stay very close to the general structure of AHL with minimal modifications in some functional groups. (Fig. 1)





Figure 1 : The general structure of AHL and designed molecules.

We preferred to stay as close as possible to the lactone-acyl scaffold to design some novel QSI candidates (Fig. 2). Structure activity relationships (SAR) calculations theoretically supported the molecules that were subsequently synthesized.

Synthesized analogues were tested for their anti QSI activities. Modifying the site of the functional groups would help us to sort out the possibilities which would lead to the discovery of the pharmacophore shape of the AHL binding site and design the best possible inhibitors.



$R^1 = \text{CH}_3, \text{C}_2\text{H}_5, \text{C}_4\text{H}_9$ $R^2 = \text{Cl}, \text{CH}_3$ $R^3 = \text{CH}_3$

Figure 2: The structural similarity between (A) the main AHL molecule and (B) our candidates.

2. GENERAL INFORMATION

2.1 Antibiotics and Bacteria

“When bacteria overcome the cutaneous or mucosal barriers and penetrate body tissues, a bacterial infection sets in. Frequently the body succeeds in removing the invaders, without manifestations of disease, by mounting an immune response. If bacteria multiply faster than the body’s defense can destroy them; infectious disease develops with manifestations, e.g., purulent wound infection or urinary tract infection. Appropriate treatment employs substances that injure bacteria and thereby prevent their further multiplication, without harming the cells of the host (Fig. 3). “⁵




Figure 3: Appropriate treatment that injures bacteria without harming cells of the host.⁵

Antibiotics are produced by microorganisms (fungi, bacteria) and are directed “against life” at any phylogenetic level (prokaryotes, eukaryotes). Chemotherapeutic agents originate from chemical synthesis. This distinction has been lost in current usage. Specific damage to

bacteria is particularly practicable when a substance interferes with a metabolic process that occurs in bacteria but not in host cells. Clearly this applies to inhibitors of cell wall synthesis, because human and animal cells lack a cell wall. The points of attack of antibacterial agents are schematically illustrated in a grossly simplified bacterial cell, as depicted in (Fig. 4)




Figure 4 : Schematic illustration in a simplified bacterial cell and major antibiotic actions.⁵

For example, polymyxins and tyrothricin are polypeptide antibiotics enhance cell membrane permeability. Due to their poor tolerability, they are prescribed in humans only for topical use. The effect of antibacterial drugs can be observed *in vitro* (Fig. 5).




Figure 5 : in vitro applications of antibiotics. ⁵

“Bacteria multiply in a growth medium under controlled conditions. If the medium contains an antibacterial drug, two results can be discerned: 1. bacteria are killed—bactericidal effect; 2. bacteria survive, but do not multiply—bacteriostatic effect. Although variations may occur under therapeutic conditions, different drugs can be classified according to their respective primary mode of action. When bacterial growth remains unaffected by an antibacterial drug, bacterial resistance is present. This may occur because of certain metabolic characteristics that confer a natural insensitivity to the drug on a particular strain of bacteria (*natural resistance*). Depending on whether a drug affects only a few or numerous types of bacteria, the terms narrow-spectrum (e.g., penicillin G) or broad-spectrum (e.g., tetracyclines) antibiotic are applied. Naturally susceptible bacterial strains can be transformed under the influence of antibacterial drugs into resistant ones (*acquired resistance*), when a random genetic alteration (mutation) gives rise to a resistant bacterium. Under the influence of the drug, the susceptible bacteria die off, whereas the mutant multiplies unimpeded. The more frequently a given drug is applied, the

more probable the emergence of resistant strains (e.g., hospital strains with multiple resistance!). Resistance can also be acquired when DNA responsible for nonsusceptibility (so-called *resistance plasmid*) is passed on from other resistant bacteria by conjugation or transduction.”⁵

2.2 Quorum Sensing

“Quorum sensing (QS) is a type of decision-making process used by decentralized groups to coordinate behavior. Many species of bacteria use QS to coordinate their gene expression according to the local density of their population. Similarly, some social insects use QS to make collective decisions about where to nest. In addition to its function in biological systems, QS has several useful applications for computing and robotics.

Quorum sensing can function as a decision-making process in any decentralized system, as long as individual components have a means of assessing the number of other components they interact with and a standard response once a threshold number of components is detected.”¹⁰

Some of the best-known examples of QS come from studies of bacteria. Bacteria use QS to coordinate certain behaviors based on the local density of the bacterial population. Quorum sensing can occur within a single bacterial species as well as between diverse species, and can regulate a host of different processes, essentially serving as a simple communication network. A variety of different molecules can be used as signals. Common classes of signaling molecules are oligopeptides in Gram-positive bacteria, *N*-Acyl Homoserine Lactones (AHL) in Gram-negative bacteria and a family of autoinducers known as AI-2 in both Gram-negative and Gram-positive bacteria.⁷

Although QS was originally used to describe *N*-acylhomoserine lactone (AHL)-dependent cell-to-cell communication in Gram-negative bacteria, QS signal molecules exhibit significant chemical diversity (Fig. 6).




Figure 6 : Structures of some bacterial QS signal molecules

Where such molecules are responsible for inducing their own biosynthesis, they are referred to as “autoinducers”. Although no “universal” bacterial QS language has yet been discovered, the

autoinducer-2(AI-2)/LuxS QS system is shared by both Gram-negative and Gram-positive bacteria. In addition, many bacteria employ more than one QS signal molecule from the same or a different chemical class, the activities of which may be coordinated via interacting QS systems, each of which incorporates a signal molecule synthase and a sensor/receptor.^{8,9,10}

QS controls secondary metabolism, bioluminescence, protein secretion, motility, virulence factor production, plasmid transfer, and biofilm maturation in diverse bacteria.^{8,10}

As a result, QS has attracted considerable industrial interest, particularly as a target for novel antibacterial agents that attenuate bacterial virulence rather than growth.¹¹ Because bacteria cohabit ecosystems with many other organisms, it is perhaps not surprising to discover that QS signals can modulate the behavior of both bacteria other than the QS signal producer itself and of higher organisms, in ways advantageous for bacterial survival.¹⁰

Conversely, higher organisms manipulate QS by producing signal mimics, by modulating QS pathways through the action of cytokines, by blocking QS through the deployment of inhibitors, or via the enzymatic inactivation of QS signals.

Two recent publications in this rapidly expanding field provide exciting new insights into the chemical diversity, evolution, and adaptability of AHL-dependent QS signal transduction pathways¹² and their effects on the host immune response¹³

2.2.1 N-Alkanoyl- and N-aroyl-Homoserine Lactone-Dependent QS

AHL-mediated QS appears to be employed exclusively by Gram-negative bacteria, including beneficial and pathogenic species, because no AHL-producing Gram-positive bacteria have yet been

identified.^{10,14} Most AHL producers synthesize multiple AHLs that are characterized by a homoserine lactone ring, unsubstituted in the β and γ positions, which is *N*-acylated with an acyl chain incorporating variable saturation levels and oxidation states. AHLs are exemplified by compounds with an acyl chain of 4–18 carbons that belong to either the *N*-acyl, *N*-(3-oxoacyl), or *N*-(3-hydroxyacyl) classes. AHLs with one or two double bonds in an acyl chain have also been described. The stereochemistry at the α -center of the homoserine lactone (HSL) ring is L, and the corresponding D-isomers are, in common with ring-open compounds, inactive. Consequently, it is the acyl chain moiety that confers QS signal specificity.¹⁵

2.2.2 AHL biosynthesis

AHL biosynthesis mostly depends on LuxI family proteins that use *S*-adenosylmethionine (SAM) and an acyl carrier protein (ACP) charged with the appropriate fatty acid as sources of the homoserine lactone (HSL) and acyl chain, respectively (Fig. 7).^{16,17}

Although one or two compounds usually predominate, most LuxI homologs produce a range of AHLs, indicating that they exhibit some flexibility and can accept a number of different acyl-ACP donors.¹⁸ In LuxI-driven AHL biosynthesis, two separate chemical events occur. The first is the transfer of the acyl group from the ACP to the amino group of SAM, followed by lactonization and the release of the AHL and methylthioadenosine. In this reaction mechanism, SAM acts as a homoserine rather than as a methyl donor¹⁶. Structural studies of Esal and LasI (which produce predominantly *N*-[3-oxohexanoyl]-L-homoserine lactone and *N*-[3-oxododecanoyl]-L-homoserine lactone [3-oxo-C12-HSL], respectively) have highlighted a substrate-binding pocket for SAM and a

common binding site for the acyl-ACP phosphopantetheine group, which constitutes a tunnel passing through the enzyme in LasI. This is occluded in Esal, a finding that provides a partial explanation for the acyl chain specificities of the two enzymes.^{19,20}




Figure 7 : Biosynthesis of 3-oxo-C6-HSL and pC-HSL (A) Biosynthesis of *N*-(3-oxohexanoyl) homoserine lactone (3-oxo-C6-HSL) via the charged acyl carrier protein and either LuxI or RpaI. (B) Biosynthesis of pC-HSL via the charged acyl carrier protein and either LuxI or RpaI.

Once produced, AHLs diffuse across the cell envelope and subsequently accumulate within the extracellular environment until a feedback concentration sufficient to activate a target LuxR family protein has been achieved. AHLs bind to and activate LuxR proteins directly such that the LuxR/AHL complex activates or represses one or more target genes that often include the AHL synthase gene, thus establishing a positive autoinduction circuit in which the AHL signal also controls its own biosynthesis.²¹ (Fig. 8)




Figure 8 : AHL in binding site target LuxR family protein ²²

2.2.3 Biofilm Formation

The formation of a biofilm begins with the attachment of free-floating microorganisms to a surface. These first colonists adhere to the surface initially through weak, reversible van der Waals forces. If the colonists are not immediately separated from the surface, they can anchor themselves more permanently using cell adhesion structures such as pili.

The first colonists facilitate the arrival of other cells by providing more diverse adhesion sites and beginning to build the matrix that holds the biofilm together. Some species are not able to attach to a surface on their own but are often able to anchor themselves to the matrix or directly to earlier colonists. It is during this colonization that the cells are able to communicate via QS using such products as AHL. Once colonization has begun, the biofilm grows through a combination of cell division and recruitment. The final stage of biofilm formation is known as development, and is the stage in which the biofilm is established and may only change in shape and size. The development of a biofilm may allow for the aggregate cell colony(ies) to be increasingly antibiotic resistant.(Fig. 9)




Figure 9: The five stages of biofilm development.

Each stage of development in the diagram is paired with a photomicrograph of a developing *P. aeruginosa* biofilm. All photomicrographs are shown to the same scale. ²³

2.2.4 Biofilms and infectious diseases

Biofilms have been found to be involved in a wide variety of microbial infections in the body, by one estimate 80% of all infections.²⁴ Infectious processes in which biofilms have been implicated include common problems such as urinary tract infections, catheter infections, middle-ear infections, formation of dental plaque, gingivitis, coating contact lenses, and less common but more lethal processes such as endocarditis, infections in cystic fibrosis, and infections of permanent indwelling devices such as joint prostheses and heart valves. More recently it has been noted that bacterial biofilms may impair cutaneous wound healing and reduce topical antibacterial efficiency in healing or treating infected skin wounds.

It has recently been shown that biofilms are present on the removed tissue of 80% of patients undergoing surgery for chronic sinusitis. The patients with biofilms were shown to have been denuded of cilia and goblet cells, unlike the controls without biofilms who had normal cilia and goblet cell morphology.²⁵

Biofilms were also found on samples from two of 10 healthy controls mentioned. The species of bacteria from interoperative cultures did not correspond to the bacteria species in the biofilm on the respective patient's tissue. In other words, the cultures were negative though the bacteria were present.²⁶

Biofilms can also be formed on the inert surfaces of implanted devices such as catheters, prosthetic cardiac valves and intrauterine devices.²⁷

New staining techniques are being developed to differentiate bacterial cells growing in living animals, e.g. from tissues with allergy-inflammations.²⁸

2.2.5 *P. aeruginosa* biofilms

The achievements of medical care in industrialised societies are markedly impaired due to chronic opportunistic infections that have become increasingly apparent in immunocompromised patients and the aging population. Chronic infections remain a major challenge for the medical profession and are of great economic relevance because traditional antibiotic therapy is usually not sufficient to eradicate these infections. One major reason for persistence seems to be the capability of the bacteria to grow within biofilms that protects them from adverse environmental factors. *P. aeruginosa* is not only an important opportunistic pathogen and causative agent of emerging nosocomial infections but can also be considered a model organism for the study of diverse bacterial mechanisms that contribute to bacterial persistence. In this context the elucidation of the molecular mechanisms responsible for the switch from planktonic growth to a biofilm phenotype and the role of inter-bacterial communication in persistent disease should provide new insights in *P. aeruginosa* pathogenicity, contribute to a better clinical management of chronically infected patients and should lead to the identification of new drug targets for the development of alternative anti-infective treatment strategies.²⁹

In recent years, the micro-organism on which most QS related studies have been initiated is *P. aeruginosa*. *P. aeruginosa* is an important human pathogen which is responsible for opportunistic infections in cancer, AIDS and cystic fibrosis (CF) patients (10-12). A wide variety of extracellular enzymes contribute to the virulence of *P. aeruginosa*. These include elastase, protease, hemolysins, exotoxin A, rhamnolipid biosurfactants and phospholipase. These exofactors are collectively capable of causing extensive tissue damage in humans and other mammals.³⁰

2.2.6 Host defense and biofilm

Elongation factor 2 is a protein that in humans is encoded by the *EEF2* gene. This gene encodes a member of the GTP-binding translation elongation factor family. This protein is an essential factor for protein synthesis. It promotes the GTP-dependent translocation of the nascent protein chain from the A-site to the P-site of the ribosome. This protein is completely inactivated by EF-2 kinase phosphorylation. It is the target of diphtheria toxin and exotoxin A. The Pseudomonas exotoxin or exotoxin A is an exotoxin produced by *P. aeruginosa*. It acts at elongation factor-2. (The mechanism of the toxin is similar to that of Diphtheria toxin.) Diphtheria toxin is a single polypeptide chain of 535 amino acids consisting of two subunits linked by disulfide bridges. Binding to the cell surface of the less stable of these two subunits allows the more stable part of the protein to penetrate the host cell. It catalyzes the ADP-ribosylation of eukaryotic elongation factor-2 (eEF2), inactivating this protein. It does so by ADP-ribosylating the unusual amino acid diphthamide. In this way, it acts as a RNA translational inhibitor. The exotoxin A of *P. aeruginosa* uses a similar mechanism of action.^{31, 32, 33}

2.3 Inhibitors Activity

As the population of bacteria increases so too does the QS molecules (QSMs) concentration, until some apparent threshold is reached at which all the bacteria switch on a behavioural trait; the population at this stage is sometimes referred to as being in a quorate state. On a more biochemical level, QSMs diffusing from the external media bind with an appropriate protein (QSP), located within the bacterium, to form a complex (Fig. 10). This QSM-QSP complex in turn binds to a region of DNA on the bacterium's chromosome (known as a *lux*-box) (Fig. 10), inducing or enhancing behavioural characteristics, as well

as the up-regulation of QSM production. In view of this self-induced up-regulation in QSM production, QSMs are often referred to as autoinducers. The *lux*-box bound QSM-QSP complex provides a stable base for the complexes involved in gene expression, namely RNA polymerase (RNAP), to activate the QS genes. However, even with an empty *lux*-box the RNAP can activate these genes, providing background production of QSMs, but this process is considerably more unstable. The system illustrated in (Fig. 10), represents the relatively simple QS process involved in bioluminescence in *V. fischeri*, for which there is only a single QSM. Our experimental work towards the verification of the model discussed in this thesis focuses on *P. aeruginosa*, whose QS system is more complex, involving two or more QSMs. Here, the primary QSM, together with the primary QSP, up-regulates production not only of itself and some virulence factors, but also of the secondary QSM and QSP, the latter system being involved in the upregulation of a number of other virulence factors.

We considered the model system illustrated in (Fig. 10), which focuses on the response of a single cell to external QSM concentrations. We proposed that QS works by the switching between two stable steady-state solutions, reflecting relatively low and high rates of QSM production, whereby increasing the population density causes the shift from low to high production rates.

The most promising mechanism for inhibiting QSP activation is the use of AHL analogues that act as antagonists for 3O-C12-HSL and C4-HSL. These molecules would most likely be similar in structure to the natural AHLs produced by *P. aeruginosa* and would compete for binding to LasR proteins. Structural variations of the 3O-C12-HSL and C4-HSL molecules have revealed epitopes that are important for the activation and inhibition of LasR activity.³⁴ (Fig. 10)




Figure 10 : The schematic illustration of QS regulation inside the bacterium cell. **(1)** the binding of the QSI and QSP (LuxR) **(2)** the binding of the QSI-QSP complex to *lux*-box induces activation of the quorum sensing genes from a down-regulated state (grey background) to **(3)** an up-regulated one (white background).

The mechanism of action of our designed molecules is in the shape of making a interaction with QSP which lead to structural change and result in a stereochemical abnormality that blocks *lux*-box regulation. As it is shown in (Fig. 11) the antagonistic analogues of the cognate AHLs compete for binding to QSP but do not result in the activation of the protein. This pair with *lux*-Box inhibits gene translation and thus protein production. This step is important from the standpoint of the inhibition of the virulence factor production caused by the biofilm formation in pathogenic microorganisms such as *P. aeruginosa*.




Figure 11: Schematic illustration of QSI inside the bacterium cell. **(1)** the binding of the QSI and QSP (LuxR) and the formation of the abnormal complex **(2)** the binding the QSI-QSP complex to *lux*-box blocks *lux*-box regulation.

2.4 Microwave Assisted Synthesis

It has long been known that molecules undergo excitation with electromagnetic radiation. (Fig. 12)³⁵

This effect is utilized in household microwave ovens to heat up food. However, chemists have only been using microwaves as a reaction methodology for a few years. Some of the first examples gave amazing results, which led to a flood of interest in this novel technique.




Figure 12 : A schematic illustration of electromagnetic radiation in a microwave synthesizer, in which the red dots represent higher enthalpy/entropy.

The water molecule is the target for microwave ovens in the home; like any other molecule with a dipole, it absorbs microwave radiation. Microwave radiation is converted into heat with high efficiency, so that "superheating" becomes possible at ambient pressure. Enormous accelerations in reaction time can be achieved, if superheating is performed in closed vessels under high pressure; a reaction that takes several hours under conventional conditions can be completed over the course of minutes.³⁶

2.4.1 Thermal vs. Nonthermal Effects

Excitation with microwave radiation results in the molecules aligning their dipoles within the external field. Strong agitation, provided by the reorientation of molecules, in a phase with the electrical field excitation, causes an intense internal heating. The question of whether a nonthermal process is operating can be answered simply by comparing the reaction rates between the cases where the reaction is carried out under irradiation versus conventional heating. In fact, no nonthermal effect has been found in the majority of reactions, and the acceleration is attributed to superheating alone. It is clear, though, that nonthermal effects do play a role in some reactions.³⁷

The principle of microwave synthesis offers three major benefits to chemistry development: speed, reproducibility, and a scalable approach to compound synthesis. Additionally, the significant advantages of our technical solution are ease of use, safety, verified synthesis methods to enable new users, and an efficient work flow that fits the drug discovery process.

To gain the greatest advantages offered by microwave synthesis, Personal Chemistry has implemented a system called Coherent Synthesis. Incorporating planning systems, automation, distributed system access, searchable databases and reaction optimisation kits. The technology has already proved itself to dramatically improve the quality of output from medicinal chemistry for lead optimisation in all the major pharmaceutical and biotech companies.³⁸

2.5. DESIGN OF THE ACTIVE SPECIES

2.5.1. Scope of the study and design of the active species

A human body carries 10^{12} microorganisms versus 10^{10} host cells. This means that the human body is in perfect balance with the microorganism domain. To use antibiotics particularly when not properly justified may turn out to be hurting this balance. The most suitable way to treat a bacterial infection should be through host system's defence forces which would selectively identify the invaders and destroy them. But then external help is needed. This help must not interfere with the rest of the microorganisms but keep the invaders from being harmful until the immunsystem can reach them. As it is explained above in detail, one way to achieve this strategy can be through QSIs.

This study aimed to design and synthesize molecules that would be competitive inhibitors for the natural QS process of some certain bacteria.

Among the QS mediators the best targets may be the ones for which the formulae have been given below. (Fig. 13)




Figure 13: There are many sites on these molecules that can be modified subsequently turning them into inhibitors.


We decided to keep the side chain mainly as it was on the original molecule making some changes such as the length, and the number of oxo groups. AHLs were inserted into the site of activity. Any bulky change would decrease this insertion. As the number of the atoms on the side chain vary between 7 and 13 we decided to stick to numbers 7 - 10 incorporating one of the oxo groups into the ring system. The main impetus for this application was finding that the total energy of the AHLs and the inhibitors that were designed seemed to be very close to each other. When we also added the distances and charge distributions that were also very close to each other, the new design appeared to be reasonable.

We decided to modify the cyclic head of the molecule still keeping the main characteristics of the original structure. The exocyclic nitrogen was pushed into the ring just at the attachment point. One of the ways to potentiate the binding of the new molecules was to enhance the

lipophilicity. The best way to do that would be to incorporate a phenyl ring. The results of the theoretical log P calculations suggested an increase in the lipophilicity of the projected molecules. As the models suggest, there are two modes that the incorporation can be made, either at the end of the straight side chain or at the other end of the molecule on/in the lactone ring. The benzene ring can be incorporated into the molecule either as phenyl group or fused. Structural studies revealed the fact that when the benzene ring was inserted as a phenyl ring into any corner of the lactone ring the geometry was drastically disturbed and the independent free rotation of the benzene ring impeded the binding. When fused to the lactone ring this free rotation was canceled and a smooth geometry was obtained. Therefore we preferred the latter case imitating benzo furan and by taking the nitrogen in as benzoxazolone.

The final molecule was benzoxazoloneamide provided it would dock with the site of activity. Studies revealed that the removal of one of the oxo groups would lead to easier synthesis if the activity was not altered. In fact good activity was observed with better results. The compounds that were synthesized in this study appear in (Table 1).

Table 1 : List of derivatives of synthesized candidates and substitutions.



Code Name	n	R ₁	R ₂
AMM33	8	-H	-H
AMM34	6	-H	-H
AMM40	5	-H	-H
AMM37	8	-Cl	-H
AMM38	6	-Cl	-H
AMM39	5	-Cl	-H
AMM43	8	-H	-CH ₃
AMM44	6	-H	-CH ₃
AMM45	5	-H	-CH ₃
AMM46	5	CH ₃	-H

The following phase of design was used to adjust the overall physicochemical properties through suitable substitutions on the benzene ring. Meanwhile the results of the QSI activity were also taken into consideration, e.g. the activity of the derivative that carried the methyl substitution at position 5 did not turn out to be positive. This mode of substitution did not continue and changed into position 6. Only one of these derivatives turned out to show activity. The others exhibited either antibacterial activity or no activity at all.

In order to optimize the interactions of the designed molecules with the site of activity the following studies were also executed: Lipophilic/hydrophilic balance, Stereochemical suitability, Charge distribution suitability,

3. MATERIALS AND METHODS

All chemicals and solvents were purchased locally from Merck AG and Aldrich Chemicals.

3.1 Chemistry

Microwave reaction was carried out in MicroSYNTH Microwave Labstation at 1600 W (2 magnetrons 800W x2) (Milestone S.r.l. Italy). ^1H NMR spectra were recorded in DMSO- d_6 on a Varian Mercury 400, 400 MHz High Performance Digital FT-NMR spectrometer using tetramethylsilane as the internal standard at the NMR facility of the Faculty of Pharmacy, Ankara University. All chemical shifts were recorded as σ (ppm). Microanalyses for C, H, and N were performed on a Leco-932 at the Faculty of Pharmacy, Ankara University, Ankara, Turkey, and they were within the range of $\pm 0.4\%$ of the theoretical value.

The synthesis of 2(3H)-benzoxazolone^{39,40}, 5-methyl-2(3H)-benzoxazolone⁴¹, 6-methyl-2(3H)-benzoxazolone⁴² and 3-decanoyl-2(3H)-benzoxazolone⁴⁶ was previously reported.

3.1.1 General procedure for the synthesis of 2(3H)-benzoxazolone derivatives⁴⁰

The mixture of 2-aminophenol (0.1 mol) (or 4-methyl-2-aminophenol, or 5-methyl-2-aminophenol) and urea (0.3 mol) was heated to 140 °C and stirred for 10 min under microwave irradiation. The reaction mixture was poured onto crushed ice. The precipitated solid product was

collected by suction filtration, washed with water, dried and recrystallized from appropriate solvents.

3.1.2 General procedure for the synthesis of 3-acyl-2(3H)-benzoxazolone derivatives

The acyl chloride (11 mMol) was added dropwise over 15 min to a solution of 2(3H)-benzoxazolone derivatives (10 mMol) and dry TEA (11 mMol) in 10 mL of dry THF cooled at -4°C. The reaction mixture was heated to 100 °C for 20 min under microwave irradiation, added to 200 mL of ice water and stirred for 1 h. The resulting precipitate was filtered, washed with water, dried, and recrystallized from appropriate solvents.

3.2 Antibacterial Activity

3.2.1 Microdilution Method

Standard strains of *Escherichia coli* ATCC 25922, *E. coli* ATCC 35218, *P. aeruginosa* ATCC 27853, *Klebsiella pneumoniae* RSHM 574 and clinical isolates of the microorganisms that are known to be resistant to various antimicrobial agents were included in the study. *E.coli* isolate and *K. pneumoniae* isolate have Extended Spectrum β -Lactamase (ESBL) enzyme and are resistant to beta lactam antibiotics and *P.aeruginosa* isolate is resistant to gentamycin.

Standard powders of ampicillin, gentamycin sulphate, ofloxacin, tetracycline, ceftriaxon, meropenem, amoxicillin/clavulonic acid and ampicillin/sulbactam were obtained from the manufacturers.

Stock solutions of the tested compounds were dissolved in DMSO. Standard antibiotic solutions were dissolved in appropriate solvents recommended by CLSI guidelines.

Table 2 : Standard antibiotic solutions were dissolved in appropriate solvents recommended by CLSI guidelines.

Antibiotics	Solvent	Diluent
ampicillin	0.1mol/L pH:8 PBS	0.1mol/L pH:6 PBS
ampicillin/sulbactam	0.1mol/L pH:8 PBS	0.1mol/L pH:6 PBS
amoxicillin/clavulonic acid	0.1mol/L pH:6 PBS	0.1mol/L pH:6 PBS
gentamycin	Distiled water	Distiled water
tetracycline	Distiled water	Distiled water
ceftriaxon	Distiled water	Distiled water
ofloxacin	0.1 mol/L NaOH with distiled water	Distiled water
meropenem	Distiled water	Distiled water

All bacterial isolates were subcultured in Mueller Hinton Agar (MHA) plates and incubated overnight at 37 °C.

Stock solutions of the tested compounds and standard drugs were diluted two-fold in the wells of the microplates so the solution of the synthesized compounds were prepared at 1024, 512, 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5 µg/mL concentrations and standard drugs were prepared at 512, 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625, 0.03, 0.015, 0.008, 0.004, 0.002, 0.001 µg/mL concentrations.

Bacterial susceptibility testing was performed according to the guidelines of Clinical and Laboratory Standards Institute (CLSI) M100-S16¹. Mueller Hinton Broth (MHB) was added to each well of the microplates. The bacterial suspensions used for inoculation were prepared at 10^5 CFU/mL by diluting fresh cultures at McFarland 0.5 density (10^7 CFU/mL). Suspensions of the bacteria at 10^5 CFU/mL concentration were inoculated to the two fold-diluted solution of the compounds. There were 10^4 CFU/mL bacteria in the wells after inoculations. A 10 μ l bacteria inoculum was added to each well of the microplates. Microplates were incubated at 37 °C overnight. After incubation, the lowest concentration of the compounds that completely inhibits macroscopic growth was determined and reported as minimum inhibitory concentrations (MICs).

All solvents and diluents, pure microorganisms and pure media were used in control wells. All the experiments were done in 3 parallel series.⁴⁴

3.3 Quorum Sensing Inhibitory Activity

3.3.1 Test for the inhibition of violacein production in *Chromobacterium violaceum*

The quorum sensing inhibitory activity of QS analogues was assayed by the agar well-diffusion test. Violacein production was determined on agar plates employing *C. violaceum* ATCC 12472, *C. violaceum* CV026 (a mini-Tn5 mutant) and *C. violaceum* VIR07 indicator organisms. In *C. violaceum* ATCC 12472, production of a purple pigment, violacein, is under the control of a QS system. This wild-type strain produces and responds to the cognate autoinducer molecules C6-AHL and C4-AHL. *C. violaceum* CV026 is a mutant of the wild-type strain that is unable to synthesize its own C6-HSL, but it retains the ability to respond

C4-AHL and C6-AHL [12]. QSI compounds inhibit production of violacein in both cases, making these strains ideal for screening.

Five mL of molten LB agar (0.3% w/v) were inoculated with 50 of a culture of either the *C. Violaceum* ATCC 12472, *C. violaceum* CV026 or *C. violaceum* VIR07 grown overnight in LB. *C. violaceum* CV026 and *C. violaceum* VIR07 were supplemented with C6-AHL (Fluka) and C12-AHL (Fluka) respectively. The agar culture solution was immediately poured over the surface of prewarmed LB agar plates. Up to 75 of the extracts to be tested were pipetted into wells punched in the solidified agar with a sterile cork borer. The plates were incubated overnight at 30 °C and examined for violacein production. QS inhibition was detected by a colorless, opaque, but viable, halo around the wells. Organic solvents themselves were also used as controls.


3.3.2 Violacein extraction

Violacein extraction was carried out according to Choo et al. 2006.⁴⁵ Briefly, 1 ml culture from flasks containing test compounds was centrifuged at 13000 rpm for 10 minutes to precipitate the violacein. The supernatant was discarded and the pellet was solubilised in 1 ml of DMSO. The solution was vortexed to completely solubilize violacein and centrifuged at 13000 rpm to remove the cells. The extracted violacein was quantified using spectrophotometer (optical density at 585 nm wavelength [OD585]).

4. RESULTS


4.1 Chemical Results

3-Decanoyl-1,3-benzoxazol-2(3H)-one (AMM33)




Recrystallized from ethanol to yield 68%; FT-IR (KBr), cm^{-1} : 1788, 1726 ($\text{C}=\text{O}$), ^1H NMR (DMSO-d_6) δ 7.97–7.95 (1H, m, benzoxazolone H^7), 7.42–7.40 (1H, m, benzoxazolone H^5), 7.31–7.26 (2H, m, benzoxazolone H^4 , H^6), 3.01 (2H, t, $-\text{CH}_2-\text{CO}-$), 1.64 (2H, m, $-\text{CH}_2\text{CH}_2\text{CO}-$), 1.34–1.26 (12H, m, CH_2), 0.86 (3H, t, CH_3). Anal. Calc. for $\text{C}_{17}\text{H}_{23}\text{NO}_3$: C, 70.56; H, 8.01; N, 4.84. Found: C, 70.20; H, 8.14; N, 4.91%.

3-Octanoyl-1,3-benzoxazol-2(3H)-one (AMM34)




Recrystallized from ethanol to yield 66%; FT-IR (KBr), cm^{-1} : 1789, 1726 ($\text{C}=\text{O}$), ^1H NMR (DMSO-d_6) δ 7.97–7.95 (1H, m, benzoxazolone H^7), 7.42–7.40 (1H, m, benzoxazolone H^5), 7.31–7.26 (2H, m, benzoxazolone H^4 , H^6), 3.01 (2H, t, $-\text{CH}_2-\text{CO}-$), 1.64 (2H, m, $-\text{CH}_2\text{CH}_2\text{CO}-$), 1.36–1.27 (8H, m, CH_2), 0.87 (3H, t, CH_3). Anal. Calc. for $\text{C}_{15}\text{H}_{19}\text{NO}_3$: C, 68.94; H, 7.33; N, 5.36. Found: C, 68.42; H, 7.33; N, 5.42%.

3-Heptanoyl-1,3-benzoxazol-2(3H)-one (AMM40)




Recrystallized from ethanol to yield 67%; FT-IR (KBr), cm^{-1} : 1803, 1730 (C=O), ^1H NMR (DMSO- d_6) δ 7.94–7.92 (1H, m, benzoxazolone H^7), 7.39–7.37 (1H, m, benzoxazolone H^5), 7.29–7.23 (2H, m, benzoxazolone H^4 , H^6), 2.99 (2H, t, $-\text{CH}_2-\text{CO}-$), 1.62 (2H, m, $-\text{CH}_2\text{CH}_2\text{CO}-$), 1.35–1.24 (6H, m, CH_2), 0.85 (3H, t, CH_3). ^{13}C NMR (DMSO- d_6) δ 172.44 (C=O), 150.78 (C=O), 141.82 (aromatic H), 127.85 (aromatic H), 124.82 (aromatic H), 124.36 (aromatic H), 115.08 (aromatic H), 109.72 (aromatic H), 35.82 (CH_2), 30.98 (CH_2), 28.00 (CH_2), 23.09 (CH_2), 21.92 (CH_2), 13.84 (CH_3) Anal. Calc. for $\text{C}_{14}\text{H}_{17}\text{NO}_3$: C, 68.00; H, 6.93; N, 5.66. Found: C, 67.89; H, 6.97; N, 5.74%.

5-Chloro-3-decanoyl-1,3-benzoxazol-2(3H)-one (AMM37)




Recrystallized from ethanol to yield 85%; FT-IR (KBr), cm^{-1} : 1796, 1724 (C=O), ^1H NMR (DMSO- d_6) δ 7.93 (1H, d, 5-chlorobenzoxazolone H^4 $J=2.4$ Hz), 7.46 (1H, d, 5-chlorobenzoxazolone H^7 $J=8.8$ Hz), 7.36 (1H, dd, 5-chlorobenzoxazolone H^6 $J=8.6$ Hz, 2 Hz), 2.99 (2H, t, $-\text{CH}_2-\text{CO}-$), 1.63 (2H, m, $-\text{CH}_2\text{CH}_2\text{CO}-$), 1.34–1.25 (12H, m, CH_2), 0.85 (3H, t, CH_3). Anal. Calc. for $\text{C}_{17}\text{H}_{22}\text{ClNO}_3$: C, 63.06; H, 6.85; N, 4.33. Found: C, 62.93; H, 7.21; N, 4.43%.

5-Chloro-3-octanoyl-1,3-benzoxazol-2(3H)-one (AMM38)




Recrystallized from ethanol to yield 66%; FT-IR (KBr), cm^{-1} : 1793, 1724 (C=O), ^1H NMR (DMSO- d_6) δ 7.92 (1H, d, 5-chlorobenzoxazolone H^4 $J=2.4$ Hz), 7.45 (1H, d, 5-chlorobenzoxazolone H^7 $J=8.4$ Hz), 7.35 (1H, dd, 5-chlorobenzoxazolone H^6 $J=8.4$ Hz, 2.4 Hz), 2.99 (2H, t, $-\text{CH}_2-\text{CO}-$), 1.63 (2H, m, $-\text{CH}_2\text{CH}_2\text{CO}-$), 1.36-1.27 (8H, m, CH_2), 0.87 (3H, t, CH_3). Anal. Calc. for $\text{C}_{15}\text{H}_{18}\text{ClNO}_3$: C, 60.91; H, 6.13; N, 4.74. Found: C, 60.50; H, 6.46; N, 4.84%.

5-Chloro-3-heptanoyl-1,3-benzoxazol-2(3H)-one (AMM39)




Recrystallized from ethanol to yield 71%; FT-IR (KBr), cm^{-1} : 1793, 1723 (C=O), ^1H NMR (DMSO- d_6) δ 7.91 (1H, d, 5-chlorobenzoxazolone H^4 $J=2.4$ Hz), 7.45 (1H, d, 5-chlorobenzoxazolone H^7 $J=8.4$ Hz), 7.35 (1H, dd, 5-chlorobenzoxazolone H^6 $J=8.4$ Hz, 2.4 Hz), 2.99 (2H, t, $-\text{CH}_2-\text{CO}-$), 1.63 (2H, m, $-\text{CH}_2\text{CH}_2\text{CO}-$), 1.39-1.27 (6H, m, CH_2), 0.88 (3H, t, CH_3). Anal. Calc. for $\text{C}_{14}\text{H}_{16}\text{ClNO}_3$: C, 59.68; H, 5.72; N, 4.97. Found: C, 59.31; H, 5.72; N, 5.11%.

3-Decanoyl-6-methyl-1,3-benzoxazol-2(3H)-one (AMM43)




Recrystallized from ethanol to yield 41%; FT-IR (KBr), cm^{-1} : 1792, 1719 (C=O), ^1H NMR (DMSO- d_6) δ 7.82 (1H, d, 6-methylbenzoxazolone H^4), 7.24 (1H, s, 6-methylbenzoxazolone H^7), 7.08 (1H, d, 6-methylbenzoxazolone H^5), 2.99 (2H, t, $-\text{CH}_2-\text{CO}-$), 2.35 (3H, s, CH_3), 1.63 (2H, m, $-\text{CH}_2\text{CH}_2\text{CO}-$), 1.33-1.25 (12H, m, CH_2), 0.85 (3H, t, CH_3). Anal. Calc. for $\text{C}_{18}\text{H}_{25}\text{NO}_3$: C, 71.26; H, 8.31; N, 4.62. Found: C, 71.05; H, 8.41; N, 4.69%.

6-Methyl-3-octanoyl-1,3-benzoxazol-2(3H)-one (AMM44)




Recrystallized from ethanol to yield 38%; FT-IR (KBr), cm^{-1} : 1786, 1718 (C=O), ^1H NMR (DMSO- d_6) δ 7.82 (1H, d, 6-methylbenzoxazolone H^4), 7.24 (1H, s, 6-methylbenzoxazolone H^7), 7.08 (1H, d, 6-methylbenzoxazolone H^5), 3.00 (2H, t, $-\text{CH}_2-\text{CO}-$), 2.35 (3H, s, CH_3), 1.64 (2H, m, $-\text{CH}_2\text{CH}_2\text{CO}-$), 1.33-1.27 (8H, m, CH_2), 0.87 (3H, t, CH_3). Anal. Calc. for $\text{C}_{16}\text{H}_{21}\text{NO}_3$: C, 69.79; H, 7.69; N, 5.09. Found: C, 69.34; H, 7.92; N, 5.14%.

3-Heptanoyl-6-methyl-1,3-benzoxazol-2(3H)-one (AMM45)



Recrystallized from ethanol to yield 35%; FT-IR (KBr), cm^{-1} : 1785, 1718 ($\text{C}=\text{O}$), ^1H NMR ($\text{DMSO}-d_6$) δ 7.82 (1H, d, 6-methylbenzoxazolone H^4), 7.24 (1H, s, 6-methylbenzoxazolone H^7), 7.08 (1H, d, 6-methylbenzoxazolone H^5), 3.00 (2H, t, $-\text{CH}_2-\text{CO}-$), 2.35 (3H, s, CH_3), 1.63 (2H, m, $-\text{CH}_2\text{CH}_2\text{CO}-$), 1.35-1.27 (6H, m, CH_2), 0.87 (3H, t, CH_3). Anal. Calc. for $\text{C}_{15}\text{H}_{19}\text{NO}_3$: C, 68.94; H, 7.33; N, 5.36. Found: C, 68.63; H, 7.28; N, 5.40%.

3-Heptanoyl-5-methyl-1,3-benzoxazol-2(3H)-one (AMM46)



Recrystallized from ethanol to yield 53%; FT-IR (KBr), cm^{-1} : 1793, 1723 ($\text{C}=\text{O}$), ^1H NMR ($\text{DMSO}-d_6$) δ 7.78 (1H, s, 5-methylbenzoxazolone H^4), 7.25 (1H, d, 5-methylbenzoxazolone H^7), 7.08 (1H, d, 5-methylbenzoxazolone H^6), 2.98 (2H, t, $-\text{CH}_2-\text{CO}-$), 2.34 (3H, s, CH_3), 1.62 (2H, m, $-\text{CH}_2\text{CH}_2\text{CO}-$), 1.36-1.25 (6H, m, CH_2), 0.86 (3H, t, CH_3). Anal. Calc. for $\text{C}_{15}\text{H}_{19}\text{NO}_3$: C, 68.94; H, 7.33; N, 5.36. Found: C, 68.64; H, 7.28; N, 5.43%.

4.2 Biological Activities Results

4.2.1 Antibacterial activity results

A list of antibacterial activities of our candidate in comparison with classic test antibiotics activities. (Table 3)

Table 3 : List of antibacterial activities of our candidate in comparison with classic test antibiotics

	A	B	C	D	E	F	G
AMM33	64	64	64	64	32	32	64
AMM34	128	128	128	64	64	64	128
AMM37	128	128	128	64	64	64	128
AMM38	128	128	128	64	64	64	128
AMM39	128	128	128	64	64	64	128
AMM40	128	128	128	64	64	64	128
AMM43	128	128	128	64	64	64	128
AMM44	128	128	128	64	64	64	128
AMM45	128	128	128	64	64	<4	128
AMM46	128	128	128	64	64	128	128
Ampicilin	2	-	>32	-	-	0.5	>32
Gentamicin	0.25	-	>16	1	>8	0.5	0.25
Ofloxacin	0.015	-	>8	1	2	0.25	0.5
Tetracycline	0.5	-	>8	8	8	0.25	4
Ceftriaxone	0.12	-	>32	64	64	2	<0.25*
Meropenem	0.008	-	<0.25	1	0.015	0.03	<0.25
Ampicillin sulbactam	-	16	-	-	-	-	-
Amoxicillin Clavulonic acid	-	16	-	-	-	-	-

A: *E. Coli* ATCC 25922,

B: *E. Coli* ATCC 35218th

C: *E. Coli* isolares,

D: *P. aeruginosa* ATCC 27853,

E: *P.aeruginosa* isolates,

F: *Klebsiella pneumoniae* RSHC 574,

G: *K. pneumoniae* isolates

*: ESBL-producing *Klebsiella spp. E. coli* strains in vitro as cephalosporins and sensitive to be shown, but can be clinically resistant to treatment with these drugs.

Candidate codes AMM33, AMM34 and AMM45 due to their strong antibacterial activities eliminated from QSI standard tests.

Molecules which have antibacterial activities may cause extensive damage in both membrane and chemistry of QS test bacteria which are selective just for QSI molecules.

4.2.2 QSI Activity Results

4.2.2.1 Inhibition of violacein production.

The inhibition of QS by synthetic QS analogues was followed by employing the indicator strains *Chromobacterium violaceum* ATCC12472, CV026 and CV VIR07. 10 compounds were tested for their QS inhibitory activity. The culture of *C. violaceum* ATCC12472 was grown overnight and spread onto LB plates. Each compound (75 µl) was loaded into the well as described in Materials and Methods. Lack of purple pigmentation from *C. violaceum* in the vicinity of the wells indicated the inhibitory effect of the test compounds. The same assays were also performed for CV026 and CV VIR07 by addition of C4-AHL and C12-AHL respectively. But due to strong the antibacterial effect of the test compounds against CV026 and CV VIR07, this assay did not give accurate results. Therefore, we decided to determine first the MIC levels of the compounds then extract the violacein pigment and measure the amount of violacein at 585nm in a UV-spectrophotometer.

The violacein extraction was carried out to quantify the inhibitory activity of test compounds as described in Materials and Methods. The results of these assays were given Table 4.

Results of the 1000 ppm test chemical addition are given in the table below.

Table 4 : Results of compounds caused inhibition

	CV 12472	% Inhibition	CV VIRO7	% inhibition	CV 026	% Inhibition
AMM 37	0.910	70	0.703	75	0.945	39
AMM 38	0.395	87	0.331	88	1.105	29
AMM 39	0.670	78	0.433	85	0.795	49
AMM 40	0.485	84	0.493	83	0.920	41
AMM 43	-	-	-	-	0.301	81
AMM 44	0.915	70	0.724	75	0.915	41
AMM 46	-	-	-	-	0.190	88
CONTROL *	3.065		2.865		1.554	

The results shown in the table show that 7 of the compounds caused inhibition. Two of them (AMM43 and AMM46) caused inhibition only when the CV026 and CV VIR07 de CV12472 did not show inhibition. Indicator strains produced by 1000ppm added increased the violin amount (585 nm)The bottom line of chemicals used has not been added and control wild-type produced by CV12472 in red violin amounts are given.

4.3 Molecular Modeling Study Results

On criteria of optimized application of two sample molecules AMM38 and AMM40 in both AUTODUCK 4.1 and VINA, we observed very impressive results. We run computer based drug design software using x-ray of the *p. aeruginosa* LasR ligand binding domain bound to its autoinducer 3-oxo-C(12)-acylhomoserine lactone, PDP ID No 2UV0.⁴⁶ Surface presentation of both molecules in very competitive position to ligand, AHL, are shown in (Fig. 14).




Figure 14: Molecular modeling of AMM38 and AMM40 competition with the autoinducer in binding site of quorum sensing protein LasR.

5. DISCUSSION

Quorum sensing (QS) is a type of decision-making process used by decentralized groups to coordinate behavior. Many species of bacteria use QS to coordinate their gene expression according to the local density of their population. Similarly, some social insects use QS to make collective decisions about where to nest.

Some of the best-known examples of QS come from studies of bacteria. Bacteria use QS to coordinate certain behaviors based on the local density of the bacterial population. Quorum sensing can occur within a single bacterial species as well as between diverse species and can regulate a host of different processes, essentially serving as a simple communication network. A variety of different molecules can be used as signals. Common classes of signaling molecules are oligopeptides in Gram-positive bacteria, *N*-Acyl Homoserine Lactones (AHL) in Gram-

negative bacteria and a family of autoinducers known as AI-2 in both Gram-negative and Gram-positive bacteria.

The inhibition of QS offers new hope in combatting multi-antibiotic resistant bacteria. Employing the inhibition of bacterial QS systems instead of using bactericidal or bacteriostatic strategies may find application in many different fields such as medicine, agriculture and food technology. In a world where agricultural residues constitute a big problem this approach can pave the way to a very soft antibacterial remedy. Also this approach is highly attractive in terms of medicine because it does not impose harsh selective pressure for the development and emergence of resistance as with antibiotics since QS is not directly involved in processes essential for growth of the bacteria. Furthermore, QSI compounds are not expected to eliminate beneficial bacteria co-existing in the host.

This study aimed to design and synthesize molecules that would be competitive inhibitors for the natural QS process of some certain bacteria.

Among the QS mediators, the best targets may be the ones for which the formula has been given below.





Figure 15: AHL types in *P. aeruginosa*

The compounds that have been synthesized by microwave assisted methods in this study, have the main chemical structure as follows.(Table 5)

Table 5: Main chemical structure and list of substitutions



Code Name	n	R ₁	R ₂
AMM33	8	-H	-H
AMM34	6	-H	-H
AMM40	5	-H	-H
AMM37	8	-Cl	-H
AMM38	6	-Cl	-H
AMM39	5	-Cl	-H
AMM43	8	-H	-CH ₃
AMM44	6	-H	-CH ₃
AMM45	5	-H	-CH ₃
AMM46	5	-CH ₃	-H

The synthetic routes for the synthesized compounds are outlined in (Fig.16). The starting compound, 1,3-benzoxazol-2(3H)-one was readily prepared by the reaction of urea and o-aminophenol under MWI and the procedures were in accordance with a previously published method.⁴⁰ MWI had a dramatically reduced reaction time for the synthesis of 1,3-benzoxazol-2(3H)-one, from 24 h to 10 min. Similarly, other starting rings, 5-methyl-1,3-benzoxazol-2(3H)-one and 6-methyl-1,3-benzoxazol-2(3H)-one, were prepared by the reaction of urea and 4-methyl-2-aminophenol / 5-methyl-2-aminophenol under MWI. The acylation of core rings with acyl chloride derivatives was carried out in tetrahydrofurane (THF) by using microwave assisted method. The reaction time for the synthesis of the 3-acyl-1,3-benzoxazol-2(3H)-one derivatives by the

conventional method was up to 4h longer in comparison to the microwave conditions (20 min).

The structures of the compounds were elucidated by IR, ¹H-NMR, and microanalyses. Crystallization solvents, melting points, % yields, and the spectral data of the compounds are given in the Results Part. (Fig. 16)




Figure 16: Synthetic route of the title compounds.

The results shown in the table indicate that 7 of the compounds caused quorum sensing inhibition on 3 standard QS test bacteria.

Candidate codes AMM33, AMM34 and AMM45 due to their strong antibacterial activities were eliminated from QSI standard tests. Molecules which have antibiotic activities may cause extensive damage in both the membrane and chemistry of the QS test bacteria which were selected just for their QSI molecules.

Table 6: QSI results

	CV 12472	% Inhibition	CV VIRO7	% inhibition	CV 026	% Inhibition
AMM 37	0.910	70	0.703	75	0.945	39
AMM 38	0.395	87	0.331	88	1.105	29
AMM 39	0.670	78	0.433	85	0.795	49
AMM 40	0.485	84	0.493	83	0.920	41
AMM 43	-	-	-	-	0.301	81
AMM 44	0.915	70	0.724	75	0.915	41
AMM 46	-	-	-	-	0.190	88
CONTROL	3.065		2.865		1.554	

We indicated that our agonist-based QSI design block QS by entering the AHL-binding pocket. Conversely, the mutant LuxR was still sensitive to inhibition by benzoxazol ring, indicating that they bind at a different location on the Lux-box protein.⁴⁷ As it is shown in (Fig.11) antagonistic analogues of cognate AHLs compete for binding to QSP but do not result in the activation of the protein. This pair with *lux-Box inhibits* gene translation and thus protein production. This step is important from the standpoint of the inhibition of virulence factor production caused by biofilm formation in pathogenic microorganisms such as *P. aeruginosa*.

6. CONCLUSION

The results showed that 7 of the 10 compounds which were successfully synthesized in this study, caused quorum sensing inhibition on 3 standard QS test bacteria. QSI activity for CV 12472 test bacteria was AMM38 %87, AMM40 %84, AMM39 %78, AMM37 %70, AMM44 %70, consequently in 1mg/ml concentration.

QSI activity for CV VIR07 test bacteria was AMM38 %88, AMM39 %85, AMM40%83, AMM44 %75, AMM37 %75, consequently in 1mg/ml concentration.

QSI activity for CV 026 test bacteria was AMM46 %88 and AMM43 %81, consequently in 1mg/mL concentration.

Our biological research revealed that the amount of violin pigment extracted was again determined by the more sensitive HPLC method.

This is an important human pathogen which is made of chemical substances by *P. aeruginosa* produced under the control of QS piyosianin mechanisms, such as elastase and ramnolipit to determine the effects virulence factors.

The tests are still being conducted to follow up on the above results thus expanding our research further. The design and evalution of new molecules based on these primary data will lead us to more novel active and selective molecules.

7. SUMMARY

DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITY STUDIES ON SOME NOVEL ACYL HOMOSERINE LACTONE ANALOGUES

The inhibition of QS (Quorum Sensing) offers new hope in combatting multi-antibiotic resistant bacteria. Inhibiting bacterial QS systems instead of employing bactericidal or bacteriostatic strategies may find application in many different fields, such as medicine, agriculture and food technology. In a world where agricultural residues constitute a big problem, this approach can pave the way to a very soft antibacterial remedy. Also, this approach is highly attractive in terms of medicine because it does not impose harsh selective pressure on the development and emergence of resistance, from antibiotics, since QS is not directly involved in the processes essential for the growth of bacteria. Furthermore, QSI compounds are not expected to eliminate beneficial bacteria co-existing in the host.⁴⁸

This study aimed to design and synthesize molecules that would be competitive inhibitors for the natural QS process of some certain bacteria.

3-Acyl-2(3H)-benzoxazolone derivatives that have been synthesized by microwave assisted methods in this study, have major chemical structures such as AHL inhibitors. The structures of the compounds have been elucidated by IR, ¹H-NMR, and microanalyses.

The results showed that 7 of the 10 compounds which were successfully synthesized in this study, caused quorum sensing inhibition on 3 standard QS test bacteria. QSI activity for CV 12472 test bacteria was AMM38 %87, AMM40 %84, AMM39 %78, AMM37 %70, AMM44 %70, consequently in 1mg/ml concentration. QSI activity for CV VIR07 test bacteria was AMM38 %88, AMM39 %85, AMM40%83, AMM44 %75,

AMM37 %75, consequently in 1mg/ml concentration. QSI activity for CV 026 test bacteria was AMM46 %88 and AMM43 %81, consequently in 1mg/ml concentration. Candidate codes AMM33, AMM34 and AMM45 due to their strong antibacterial activities were eliminated from QSI standard tests. Molecules which have antibiotic activities may cause wide damages in both membrane and chemistry of QS test bacteria which are selective just for QSI molecules.

Promising results of molecular Modeling for AMM38 and AMM40 in competition with autoinducer in binding site were impressive.




Figure 14: Molecular modeling of AMM38 and AMM40 competition with the autoinducer in binding site of quorum sensing protein LasR.

The tests are still being conducted to follow up on the above results and will lead us to do more extensive research. The design and evaluation of the new molecules based on these primary data will lead us to more novel, active and selective molecules.

Key words: Acyl Homoserine Lactone, Quorum Sensing, 2(3H)-Benzoxazolone

8. ÖZET

BAZI YENİ AÇILHOMOSERINLAKTON ANALOGLARININ TASARIMI, SENTEZİ VE BİYOLOJİK AKTİVİTELERİ ÜZERİNDE ÇALIŞMALAR

Bakterilerin izole varlıklar olarak yaşamadıkları, değişen ortam koşullarına uyumlarını kolaylaştırmak için karmaşık hücrelerarası haberleşme sistemleri kullanan topluluklar halinde bulundukları giderek artan bir yaygınlıkla kabul edilmektedir. Bu tip hücreler arası haberleşmenin iyi karakterize edilmiş bir örneği, çevreyi algılamadır. Çevreyi algılama, bir bakteriye kendi hücre populasyon yoğunluğunu izlemesine olanak veren autoinducer veya feromon olarak adlandırılan sinyal moleküllerinin üretimine bağlıdır. Değişik bakteri türlerinde, çeşitli fizyolojik işlemler, çevreyi algılama ile regüle edilir. Bu işlemlere örnek olarak, biyoluminesens, antibiyotik biyosentezi, biyofilm oluşumu, konjugasyon ve hayvan, bitki ve balık patojenleri tarafından oluşturulan virülens etkenlerinin üretimi verilebilir. Gram-negatif bakterilerde en yaygın olarak bulunan sinyal molekülleri N-acyl homoserine lakton türevleridir (acyl HSLs).

Yeter Çoğul Algılama (YÇA)(Quorum Sensing) toplanmamış gruplar tarafından karar mekanizmaları için kullanılan bir süreçtir. Bir çok bakteri türü YÇA'yı nüfusun yoğunluğuna göre kendi gen ifadeleri için kullanırlar. Benzer şekilde bazı sosyal böcekler yuvalarını nerede yaparlar diye YÇA'yı kullanırlar.


YÇA çalışmalarında en iyi örnekler bakteriler üzerinde yapılan çalışmalardır. Bakteriler, YÇA'yı kullanarak bakteriyel nüfusun yerel yoğunluğuna bağlı bazı davranışları düzenler. YÇA basit bir iletişim mekanizması olarak hizmet vermekte, bir tür içinde iletişimi sağlamakta, türler arası iletişimi sağlamakta veya farklı süreçleri düzenlemede

kullanılmaktadır. Çeşitli moleküller ileti için kullanılabilir. Genellikle gram pozitif bakterilerde oligopeptitler kullanılırken, gram negatiflerde N-Açil Homoserin Lakton (AHL) ve Kendini Uyarıcı (KU) (autoinducer) adlı AI-2 ler her iki tür bakteri kullanmaktadır.


YÇA'yı durdurmak antibiotiklere dirençli bakteriler ile mücadele için umut vadetmektedir. Bakteri üremesi veya ölümünden daha ziyade YÇA durdurmak, ilaç, tarım ve gıda teknolojisi gibi yeni alanlar vadetmektedir. Tarımsal kimyasal atıkların ciddi bir sorun olduğu bir dünyada, bu yöntem daha yumuşak antibakteriyal eylemlerin önünü açabilir. Ayrıca YÇA ilaç araştırmalarında çok önemli bir alandır zira çeşitli yöntemlerle bakterilerin direncini artıran meknizmalardan uzak, bakterinin temel işlevlerini doğrudan engellememektedir. En önemlisi, YÇA durduran bileşikler bakterilerin evsahibine verecekleri yararlı katkıları da engellememektedir.

Bu çalışma bazı özgün bakterilerde kullanılan YÇA sürecini durdurmak için çeşitli kompetitif antagonist moleküllerin tasarımı ve sentezini hedeflemiştir.

En iyi hedef olan YÇA arabulucuların formülleri aşağıda verilmiştir.




3-okso-C12-HSL



3-okso-C6-HSL

Bu çalışmada mikro dalga destekli sentez yöntemleri ile sentezlenen bileşiklerin ana kimyasal yapısı aşağıda verilmiştir:



Code Name	n	R ₁	R ₂
AMM33	8	-H	-H
AMM34	6	-H	-H
AMM40	5	-H	-H
AMM37	8	-Cl	-H
AMM38	6	-Cl	-H
AMM39	5	-Cl	-H
AMM43	8	-H	-CH ₃
AMM44	6	-H	-CH ₃
AMM45	5	-H	-CH ₃
AMM46	5	-CH ₃	-H

Tablodaki 10 madde için gösterilen sonuçlarda, 7 tanesi 3 farklı standart YÇA test bakterisi üzerinde YÇA inhibitör etki göstermiştir.

AMM33, AMM 34 ve AMM 45 güçlü bakterisit etkilerinden dolayı, standart YÇA testlerinden çıkartılmıştır. Bu tür güçlü antibakteriyal etkisi olan bileşikler, YÇA'lamaya duyarlı olan test bakterilerin çeperi ve kimyasında yaygın hasarlara yol açabilir.

Tablo 6: YÇA durdurucularının sonuçları

	CV 12472	% Inhibisyon	CV VIRO7	% Inhibisyon	CV 026	% Inhibisyon
AMM 37	0.910	70	0.703	75	0.945	39
AMM 38	0.395	87	0.331	88	1.105	29
AMM 39	0.670	78	0.433	85	0.795	49
AMM 40	0.485	84	0.493	83	0.920	41
AMM 43	-	-	-	-	0.301	81
AMM 44	0.915	70	0.724	75	0.915	41
AMM 46	-	-	-	-	0.190	88
KONTROL GRUBU	3.065		2.865		1.554	

Tasrladığımız m lek llerin Y A proteinine baėlanarak yapısal deėişiklik yapıp, sonra Lux-Kutusunu baėlanma noktasında işlevi durduracak steriyokimyasal d zensizliėe yol a tıldığını  ng rlmektedir. Resimde g r ld ė  gibi Y A durdurucuları AHL ile yarıřarak Y A proteinine baėlandığı halde  devin oluřmasını engellemektedirler. Lux-Kutusu ile oluřan bu yapı gen  evirisi ve protein sentezini durdurmaktadır. Bu *P. aeruginosa* gibi hastalık yapan mikroorganizmalarda biofilm oluřumu sonucu ortaya  ıkan hasta edici fakt rleri durdurmak a ısında  nemlidir.




Figure 11: Bakteri H cresinde Y A durdurucuların řematik  izimi.

(1) Y A durdurucunun Y A proteinine baėlanması (LuxR) ve anormal yapının oluřumu (2) bu ikilinin *lux-box* baėlanarak işlev durdurulmasına yol a ması.

AMM 38 ve AMM40 in bilgisayar modellemesi ile elde edilen ve AHL ile bağlanma yöresinde yarışmayı gösteren etkileyici sonuçlar, gelecek vaatetmektedir.




Figure 14: YÇA proteini LasR'e bağlanmak için KU ile yarışan AMM38 ve AMM40'ın bilgisayar modellemeleri.

Anahtar Kelimeler: Açilhomoserinlaktone, Yeterçoğul algılama, 2(3H)-Benzoksazon

REFERENCES

1. Hooper R. People Are Human-Bacteria Hybrid [online]. 2004 [cited 2009 Dec 11]. Available from: URL : <http://www.wired.com/medtech/health/news/2004/10/65252>
2. J. K. Nicholson, E. Holmes, J. C. Lindon, I. D. Wilson Nat Biotech, Vol. 22, No. 10. (2004), p. 1268-1274
3. Biofilm, wikipedia [online]. 2009 [cited 2009 Dec 11]. Available from: URL : http://en.wikipedia.org/wiki/Biofilm#cite_note-4
4. T. B. Rasmussen, M. Givskov, International Journal of Medical Microbiology, Vol 296, Issues 2-3, 2006, p. 149-161
5. H. Luellmann, K. Mohr, L. Hein, D. Bieger, Color Atlas of Pharmacology 2nd ed. New York · Thieme; (2000). p. 266
6. Quorum Sensing [online]. 2009 [cited 2009 Dec 20]. Available from: URL : http://en.wikipedia.org/wiki/Quorum_sensing
7. Miller, M. B.; Bassler, B. L. Annu. Rev. Microbiol., 55, (2001), p.165-199
8. Fuqua and Greenberg, C. Fuqua and E.P. Greenberg, Nat. Rev. Microbiol. 3 (2002), p. 685–695
9. A.M. Lazdunski, I. Ventre and J.N. Sturgis, Nat. Rev. Microbiol. 2 (2004), p. 581–592.
10. P. Williams, Microbiology 153 (2007), p. 3923–3938.
11. T. Bjarnsholt and M. Givskov, Philos. Trans. R. Soc. Lond. B Biol. Sci. 362 (2007), p. 1213–1222.

12. A.L. Schaefer, E.P. Greenberg, C.M. Oliver, Y. Oda, J.C. Huang, G. Bittan-Banin, C.M. Peres, S. Schmidt, K. Juhaszova, J.R. Sufrin and C.S. Harwood, *Nature* 454 (2008), p. 595-599
13. V.V. Kravchenko, G.F. Kaufmann, J.C. Mathison, D.A. Scott, A.Z. Katz, D.C. Grauer, M. Lehmann, M.M. Meijler, K.D. Janda and R.J. Ulevitch, *Science* 321 (2008), p. 259–263
14. P. Williams, K. Winzer, W. Chan and M. Cámara, *Philos. Trans. R Soc. Lond. B – Biol. Sci.* 362 (2007), p. 1119–1134
15. S.R. Chhabra, L. Eberl, M. Givskov, B. Philip, P. Williams and M. Cámara In: S. Schulz, Editor, *Topics in Current Chemistry. Pheromones and Other Semiochemicals Volume 2*, Springer, New York (2005), p. 279–315
16. M.I. Moré, L.D. Finger, J.L. Stryker, C. Fuqua, A. Eberhard and S.C. Winans, *Science* 272 (1996), p. 1655–1658
17. C. Fuqua and E.P. Greenberg, *Nat. Rev. Microbiol.* 3 (2002), p. 685–695
18. C.A. Ortori, S. Atkinson, S.R. Chhabra, M. Camara, P. Williams and D.A. Barrett, *Anal. Bioanal. Chem.* 387 (2007), p. 497–511
19. W.T. Watson, T.D. Minogue, D.L. Val, S. Beck von Bodman and M.E.A. Churchill, *Mol. Cell* 9 (2002), pp. 685–694.) (T.A. Gould, H.P. Schweizer and M.E.A. Churchill, *Mol. Microbiol.* 53 (2004), p. 1135–1146
20. T.A. Gould, H.P. Schweizer and M.E.A. Churchill, *Mol. Microbiol.* 53 (2004), p. 1135–1146
21. P. Williams, *Microbiology* 153 (2007), p. 3923–3938

22. M. H. KIM ; C. Won-Chan ; H. O. KANG ; J. S. LEE ; B. S. KANG ; K. Kyung-Jin ; D. Zygmunt S. ; O. Tae-Kwang ; C. H. LEE ; L. Jung-Kee ; the National Academy of Sciences of the United States of America, vol. 102, n°49, (2005), p. 17606-17611
23. [online]. 2007 [cited 2009 Dec 11]. Available from: URL : <http://grants.nih.gov/grants/guide/pa-files/PA-03-047.html>
24. NIH, National Heart, Lung, and Blood Institute [online]. 2002 [cited 2009 Dec 11]. Available from: URL : <http://grants.nih.gov/grants/guide/pa-files/PA-03-047.html>.
25. J. Sancleme, P. Webster, J. Thomas, H. Ramadan, The Laryngoscope 115 (4) (2005) p 578–82.
26. A.R. Sanderson, JG Leid, D. Hunsaker The Laryngoscope 116 (7) (2006) p1121–6
27. M.E. Auler, D. Morreira, F.F. Rodrigues, et al. Medical Mycology: (2009). 1–6.
28. W.M. Leevy, S.T. Gammon, H. Jiang, et al. Journal of the American Chemical Society 128 (51) (2006). P. 16476–7
29. Biofilm [online]. 2009 [cited 2009 Dec 20]. Available from: URL : <http://en.wikipedia.org/wiki/Biofilm>
30. G.B.TİNAZ Turk J Biol 27 (2003) p. 85-93
31. Diphtheria toxin [online]. 2009 [cited 2009 Dec 20]. Available from: URL : http://en.wikipedia.org/wiki/Diphtheria_toxin
32. Pseudomonas exotoxin [online]. 2009 [cited 2009 Dec 28]. Available from: URL : http://en.wikipedia.org/wiki/Pseudomonas_exotoxin

33. EEF2 [online]. 2009 [cited 2009 Dec 20]. Available from: URL : http://en.wikipedia.org/wiki/Elongation_factor-2
34. R. S. Smith, B. H. Iglewski J. Clin. Invest. 112: (2003), p. 1460–1465
35. MILESTONE Helping Chemists [online]. 2009 [cited 2009 Dec 20]. Available from: URL : <http://www.milestonesrl.com/analytical/products-microwave-synthesis-rotosynth-why-the-rotosynth.html>
36. Organic Chemistry Portal [online]. 2009 [cited 2009 Dec 20]. Available from: URL : <http://www.organic-chemistry.org/topics/microwave-synthesis.shtm>
37. Organic Chemistry Portal [online]. 2009 [cited 2009 Dec 25]. Available from: URL : <http://www.organic-chemistry.org/topics/microwave-synthesis.shtm>
38. Jon-Sverre Schanche Molecular Diversity Vol 7, Numbers 2- (2003) p. 291-298
39. GROENVİK, E. : "2-Oxo-benzoxazolin, Benzoxolon, 2-Oxy-benzoxazol". Bull. Soc. Chem. France, 25 (2), 178 (1876). Ref Beilstein 27 (177)
40. ŞEYMA Cankara MSc Thesis, synthesis of some 6 - (Thiazole-4-IL)-2-oxo-3H- benzoxazline derivatives and studies of their inhibitor effects on cyclooxygenase, Advisor Prof. Dr.Serdar ÜNLÜ 2007
41. Bretschneider, H.; Piekarski, G. Oxazoles and oxazolines. II. Synthesis of the ethyl ester of 2-dichloromethyl-2-oxazoline-4-carboxylic acid from the ethyl ester of serine and dichloroacetimino thio-ethyl ether. Monatshefte fuer Chemie (1954), 85 p. 1110-1118

42. Eckstein, Zygmunt. Investigation of hydroxamic acids. V. Lossen rearrangement of O-hydroxyarylhydroxamic acids. *Roczniki Chemii* (1954), 28, p. 549-60.
43. Cotellet, Nicole; Cotellet, Philippe; Lesieur, Daniel. Acylation of 2,3-dihydrobenzoxazol-2-one in a two-step method involving an acyl migration. *Synthetic Communications* (1989), 19(18), p. 3259-66
44. Clinical and Laboratory Standards Institute (CLSI) (formerly NCCLS), Performance Standards for Antimicrobial Susceptibility Testing 16th Informational Supplement. CLSI M100-S18, Clinical and Laboratory Standards Institute, 940 West Valley Road, Wayne, Pennsylvania, USA, 2008.
45. J.H. Choo, Y. Rukayadi, J.K. Hwang, *Letters in Applied Microbiology*, (2006.) p. 42637-641
46. STRUCTURE OF THE P. AERUGINOSA LASR LIGAND-BINDING DOMAIN BOUND TO ITS AUTOINDUCER [online]. 2009 [cited 2009 Dec 25]. Available from: URL
<http://www.rcsb.org/pdb/explore/explore.do?structureId=2UV0>
47. S. C. Winans, B. L. Bassler, *Chemical Communication among Bacteria*, 1st ed, ASM Press, Washington DC, (2008) p. 396
48. G. B. Tinaz, S. Ulusoy, A. Ugur, O. Ceylan, *Current Microbiology* V. 55, No 2 (2007) p. 114-118

CURRICULUM VITAE

Anooshirvan M. Miandji

Tehran. Iran 7th January 1971

EDUCATION

2005 BSc. Pharmacy Gazi University

LANGUAGES

- **Persian** Native
- **Azeri** Native
- **Turkish** Fluent (*academic*)
- **English** Advanced (*CBT 217, 2006*)
- **Arabic** Advanced reading

PUBLICATIONS

- 2010 **A Standard Dicitonary of Pharmacy** -A first illustartated guide to the most common terminology in the field of Pharmacy, classifications and molecular structures of chemicals, abbreviations, generic lists in the world market,8000 entries, European-Books, London, UK
- 2010 **Dicitonary of Pharmacy (Turkish)** - First online guide to the most common terminology in Pharmacy field, classifications and molecular structures of chemicals, abbreviations, generic lists in Turkish market,5000 entries, European Business Matching Center, London, UK, Turkey Branch
- 2010 **Magistral Formulary (Turkish)**, a unique and up-to-date resource for extemporaneous preparations which is essential for all pharmacists to know in daily pharmacy services. More than 800 formulas with directions and all essentials on compunding methods, 650 p., EGAŞ, Ankara, Turkey
- 2010 **Farsi-English/ English-Farsi Standart Dictionary** - An Up-to-date dictionary, 1200 p., 2007, [Eng.- Pers./Pers.- Eng.], 40000 entries, Hippocrene Books, NY, USA

- 2010 **Atlas of Medicinal Plants-** A practical pictorial reference for 170 common diseases and pharmaceutical dosed herbal remedies for them, Bilgi Yayinevi, Ankara, Turkey
- 2003 **Farsi-English/ English-Farsi Concise Dictionary-** An Up-to-date dictionary, 450 p., [Eng.- Pers./Pers.- Eng.], ISBN 078180860X, Hippocrene Books, NY, USA
- 1997 **Beginner's Persian-** A Beginners guide to the Persian language, 315 p., [Pers.- Eng.], ISBN 0781805678, Hippocrene Books, NY, USA
- 1996 **Digital Conversation Dictionary** A Common Phrases Dictionary, 168 p., Eng.-Tur.], Palme Publications, Ankara, Turkey
- 1994 **Modern Farsi** - An Intensive guide to the Farsi Phonological System - Tourist Guide of Iran, 304 p., 1995, [Pers.-Eng.], Mehran Publications, Tabriz, Iran

PAPERS, LECTURES AND PRESENTATIONS

- July 2008 Reportage "**Inventor Pharmacist and A Medication Reminder System**", Turkish Pharmacist's Association Bulletin
- Oct 2006 **Seminar, "Bacterial Esperanto"** Quorum Sensing and New Antibiotics, Department of Medicinal Chemistry, Faculty of Pharmacy, Gazi University
- July 2001 Report of **3rd EPSA Summer University**, Turkish Pharmacist's Association Bulletin
- Aug 2000 Report of **23rd EPSA Congress**, Turkish Pharmacist's Association Bulletin
- April 2000 **Poster Presentation, "Biotechnology in Pharmacy" - 23rd EPSA Congress**, Uppsala, Sweden, Topic Biotechnology, Official delegate

INVENTION

- 2007 **1st Place Winner** of 6. Region of Channel D TV competition
“Our Inventors”
- 1999 **INVENTION**, inventor of an electronic medication reminder
system “Pharminder”, patent pending since 2007,
www.pharminder.com

GRANTS

- 2001 TEB (Turkish Pharmacist’s Association) Travel Grant-3rd
EPSA Summer University, Istanbul, Turkey
- 2000 TEB (Turkish Pharmacist’s Association) Travel Grant- 23rd
EPSA Congress, Uppsala, Sweden
- 2000 Gazi University Travel Grant- 23rd EPSA Congress,
Uppsala, Sweden
- 1999-2000 Gazi University, Faculty of Pharmacy Alumni Education
Grants
- 1998-1999 YÖK (Turkish Higher Education Consul) Educational Grants